Clinical trial · Interventional
Comparison of the Effects of Needle Biopsy Tract Resection and Non-resection on Recurrence Rate in Patients With Primary Extremity Sarcoma
Comparison of the Effects of Needle Biopsy Tract Resection and Non-resection on Recurrence Rate in Patients With Primary Extremity Sarcoma: Study Protocol of a Randomized, Non-inferior Clinical Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This randomized, non-inferiority clinical trial aims to evaluate whether non-resection of needle biopsy tract is non-inferior to routine biopsy tract resection in terms of local recurrence in patients with primary extremity musculoskeletal sarcoma undergoing en-bloc surgical treatment. Biopsy tract resection is traditionally recommended to reduce the risk of tumor seeding; however, its benefit in reducing recurrence has not been definitively demonstrated, particularly when core needle biopsy is widely used. Also, avoiding biopsy tract resection may preserve uninvolved tissue without compromising oncologic safety. The primary objective of this study is to compare local recurrence rates between patients who undergo biopsy tract resection and those who do not. Secondary objectives include comparisons of surgical complications, functional outcomes, overall survival, and progression-free survival.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Primary | Primary Neoplasm | ALIAS | 0.90 |
| Sarcoma | Sarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| biopsy tract non-resection | Procedure | — | UNRESOLVED |
| biopsy tract resection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- tract resection group
- interventionNames
- Procedure: biopsy tract resection
- type
- ACTIVE_COMPARATOR
- label
- tract non-section group
- interventionNames
- Procedure: biopsy tract non-resection
Primary outcomes (1)
- measure
- Cumulative incidence of local recurrence at 2 years
- timeFrame
- From the date of surgery to the date of first documented local recurrence, death, or last follow-up, assessed up to 24 months after surgery.
- description
- Local recurrence is defined as radiologically or pathologically confirmed recurrence of sarcoma at or adjacent to the primary surgical site after definitive tumor resection. The cumulative incidence of local recurrence will be estimated with death treated as a competing event.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 5 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologically confirmed diagnosis of primary bone or soft tissue sarcoma of the extremities (or highly suspected sarcoma); 2. Candidate for limb-sparing surgery and capable of en-bloc resection; 3. Age ≥ 5 years; 4. ECOG performance status 0-2; 5. Able to understand and sign informed consent. Exclusion Criteria: 1. Presence of distant metastasis (e.g., lung, bone, or other sites) or unresectable skip lesions; 2. Patients deemed, based on preoperative multidisciplinary team (MDT) evaluation, unlikely to achieve adequate surgical margins and therefore only eligible for debulking or palliative surgery; 3. Patients with inconclusive needle biopsy results requiring open biopsy for definitive diagnosis; 4. Patients requiring amputation; 5. Patients who have received prior treatment for the tumor at non-participating centers; 6. Patients with an expected survival of less than 2 years; 7. Patients in whom the biopsy tract completely lies within the planned tumor resection field; 8. Patients who refuse to provide written informed consent.
References
Publications (0)
Data not yet available